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Background: Tacrolimus (TAC) is a powerful remission-inducing drug for refractory ulcerative colitis (UC). However,
it is unclear whether mucosal healing (MH) influences relapse after completion of TAC.We investigated whether MH
is related to relapse after TAC.
Patients: Among 109 patients treated with TAC, 86 patients achieved clinical remission and 55 of them underwent
colonoscopy at the end of TAC. These 55 patients were investigated.
Methods: Patients with MH at the end of TAC were classified into the MH group (n = 41), while patients without
MH were classified into the non-MH group (n = 14). These groups were compared with respect to 1) clinical
characteristics before treatment, 2) clinical characteristics on completion of treatment, and 3) the relapse rate and
adverse events rates. This is a retrospective study conducted at a single institution.
Results: 1) There was a significant difference in baseline age between the two groups before TAC therapy, but
there were no significant differences in other clinical characteristics. The NMH group was younger (MH group: 48.1
(23–79) years, NMH group: 36.3 (18–58) years, P = 0.007). Endoscopic scores showed significant differences between
the 2 groups at the end of TAC. There were also significant differences in the steroid-free rate after 24 weeks (MH
group: 85.3%, NMH group 50%, P = 0.012). There was no significant difference in the relapse rate between the 2
groups at 100 days after remission, but a significant difference was noted at 300 days (17% vs. 43%), 500 days (17%
vs. 75%), and 1000 days (17% vs. 81%) (all P < 0.05).
Conclusions: TAC is effective for refractory ulcerative colitis. However, even if clinical remission is achieved, relapse
is frequent when colonoscopy shows that MH has not been achieved. It is important to evaluate the mucosal
response by colonoscopy on completion of TAC.
Keywords: Ulcerative colitis, Tacrolimus, Mucosal healingBackground
UC is a chronic benign intestinal disease. The prevalence
of UC has increased worldwide and is expected to in-
crease further [1]. Surgery may be indicated for severe
UC, especially refractory prednisolone-resistant or
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associated with various complications [3, 4]. TAC is used
as remission induction therapy for refractory UC, and
the short-term remission rate achieved with TAC is high
[5]. However, the relapse rate at 1 year after induction of
remission by TAC is also high, in the range of 20 to 30%
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published concerning the control of UC relapse by
achieving MH [7], but it has not been clarified whether
MH influences relapse after TAC therapy. Therefore,
this study was performed to investigate the relationship
between MH and relapse of UC after TAC.Methods
At our department, TAC was administered to 109 pa-
tients from April 2016 to December 2018 (mean follow-
up period: 819 ± 781 days). TAC was given at 0.025 to
0.075 mg/kg body weight twice daily before breakfast
and dinner. Blood samples were collected daily for meas-
urement of TAC levels until the target blood concentra-
tion was reached. The TAC dose was adjusted to reach
the target trough concentration of 10 to 15 ng/mL blood
within two weeks of starting TAC remission induction
therapy.
Then, 2 to 3 weeks after the TAC concentration
was within the target range, the dose was adjusted
again to reach a new lower target concentration of 5
to 10 ng/mL.
Clinical remission was achieved in 86 patients. Colonos-
copy was performed at the end of TAC therapy in 55 pa-
tients who had agreed to receive colonoscopy (Fig. 1). All
patients received steroids before TAC. PSL was adminis-
tered to all 55 patients before initiation of TAC, so all pa-
tients had prednisolone-dependent or prednisolone-
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Fig. 1 Outline of the mucosal healing group and nonmucosal healing grouEndoscopic evaluation was performed to determine
the Mayo score and the UCEIS score [8, 9]. Before ster-
oid administration, 42 patients underwent endoscopy
(MH group: n = 33, NMH group: n = 9). MH was defined
as a Mayo score of 0 or 1 [7]. Patients who achieved MH
at the end of TAC were classified into the MH group
(group: n = 41), while patients who did not were classi-
fied into the non-MH group (group: n = 14). The Lichti-
ger score was determined as the clinical activity index
(CAI) [10]. The MH and NMH groups were compared
with respect to the following three factors: 1) clinical
characteristics before PSL, CAI, hemoglobin, albumin,
CRP (C-reactive protein), endoscopic scores (Mayo and
UCEIS) and TAC (sex, age, duration of UC, site of UC,
PSL responsiveness (dependent/resistant), CAI,
hemoglobin, albumin, CRP, endoscopic scores (Mayo
and UCEIS), and time to reach the target trough level of
TAC); 2) clinical characteristics at the end of TAC (CAI,
hemoglobin, albumin, CRP, endoscopic scores (Mayo
and UCEIS), total PSL dose during hospitalization, dur-
ation of TAC, frequency of combined azathioprine
(AZA) therapy, and steroid-free rate after 24 weeks), and
3) the relapse rate at 100 (MH group: n = 39, NMH
group: n = 15), 300 (MH group: n = 35, NMH group: n =
11), 500 (MH group: n = 32, NMH group: n = 3), and
1000 days (MH group: n = 16, NMH group: n = 3) after
achieving remission. Remission was defined as a CAI ≤4
at 4 weeks or longer after initiation of remission induc-
tion therapy. The total PSL dose during hospitalization
was the amount of PSL used until a clinical remission




performed at the end 
of TAC n=31




Ito et al. BMC Gastroenterology          (2020) 20:203 Page 3 of 7induction. Relapse was defined as the need for high-dose
intravenous steroid therapy, switching to a biologic, re-
administration of TAC, or re-administration of TAC at a
higher dose (target trough level ≥ 10 ng/dL) to induce re-
mission again.
Adverse events were defined as any undesired or unin-
tended illness or signs thereof (including abnormal la-
boratory values) occurring in subjects receiving TAC.
Statistical analysis
The results are expressed as the number of patients or
as the mean ± standard deviation. The Wilcoxon test
was used for comparisons between the 2 groups, and dif-
ferences were considered to be significant at P < 0.05.




The clinical characteristics of the MH and NMH groups
are summarized in Table 1.
Before PSL administration, there was no significant dif-
ference between the two groups in CAI MH group: 13.3
(9–19), NMH group: 13.1 (10–17), P = 0.493, hemoglobin
MH group: 11 (7.5–12.9), NMH group: 12.6 (7.9–15.1) g/
dL, P = 0.19, albumin MH group: 3.4 (1.9–4.4), NMH
group: 3.4 (2–4.6) g/dL, P = 0.889, CRP MH group: 3.9
(0.2–22.6), NMH group: 2.9 (0.04–11.9) mg/dL, P = 0.636,
or either endoscopic score (Mayo: MH group: 2.9 (2, 3),Table 1 Comparision between the mucosal healing group (MH Grou
MH G
n = 4
Data before PSL administration
CAI 13.3
Hb (g/dl) 11 (7
Alb (g/dl) 3.4 (1
CRP (mg/dl) 3.9 (0
Mayo scorea 2.9 (2
UCEIS scorea 6.6 (4
Data before TAC administration
CAI 12.9
Hb (g/dl) 12 (7
Alb (g/dl) 3.3 (1
CRP (mg/dl) 3.5 (0
Mayo score 2.9 (2
UCEIS score 6.7 (4
Time to achieve the target TAC trough level (days) 3.1 (1
Data are expressed as the mean ± standard deviation or the number of patients
Alb albumin, CRP C-reactive protein, Hb hemoglobin, Mayo scar Mayo endoscopic sc
colitis endoscopic index of severity
aColonoscopy before PSL administration was performed in 33 patients in the MH grNMH group: 3 (3), P = 0.341; UCEIS MH group: 6.6 (4–
8), NMH group: 7.4 (6–8), P = 0.236) (Table 1).
The age at initiation of treatment showed a significant
difference between the 2 groups (MH group: 48.1 (23–
79) years, NMH group: 36.3 (18–58) years, P = 0.007),
but there were no significant differences of other factors
(sex M/F MH group: 20/21, NMH group: 9/5, P = 0.396;
duration of UC MH group: 9.4 (0–33) years, NMH
group: 9.0 (0–26) years, P = 0.88; site of UC left colon/
total colon MH group: 25/16, NMH group: 8/6, P = 0.8;
steroid responsiveness (dependent/resistant) MH group:
18/23, NMH group: 6/8, P = 0.889; CAI: MH group: 12.9
(7–19), NMH group: 13.4 (11–17), P = 0.593;
hemoglobin MH group: 12 (7.5–14.9), NMH group: 12.9
(8.1–15.1) g/dL, P = 0.191; albumin MH group: 3.3 (1.7–
4.4), NMH group: 3.3 (2–4.6) g/dL, P = 0.838; CRP MH
group: 3.5 (0.04–24.1), NMH group: 2.6 (0.04–10.4) mg/
dL, P = 0.525; endoscopic scores Mayo: MH group: 2.9
(2, 3), NMH group: 3 (3), P = 0.306; UCEIS MH group:
6.7 (4–8), NMH group: 7.2 (6–8), P = 0.136); and time to
achieve the target trough level of TAC MH group: 3.1
(1–10), NMH group: 4.5 (1–9) days, P = 0.07) (Table 1).
Clinical characteristics on completion of TAC
At the end of TAC, significant differences in the endo-
scopic scores were noted between the 2 groups (Mayo
score MH group: 0.6 (0–1), NMH group: 2.2 (2, 3);
UCEIS score MH group: 1.1 (0–4), NMH group: 4.4 (4,






(9–19) 13.1 (10–17) 0.493
.5–12.9) 12.6 (7.9–15.1) 0.19
.9–4.4) 3.4 (2–4.6) 0.889
.2–22.6) 2.9 (0.04–11.9) 0.636
–3) 3 (3) 0.341
–8) 7.4 (6–8) 0.236
(7–19) 13.4 (11–17) 0.593
.5–14.9) 12.9 (8.1–15.1) 0.191
.7–4.4) 3.3 (2–4.6) 0.838
.04–24.1) 2.6 (0.04–10.4) 0.525
–3) 3 (3) 0.306
–8) 7.2 (6–8) 0.136
–10) 4.5 (1–9) 0.07
ore, ns not significant, PSL prednisolone, TAC tacrolimus, TNFα, UCEIS ulcerative
oup and 9 patients in the NMH group
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922) days, NMH group: 136.9 (70–373) days, P = 0.014)
and the steroid-free rate after 24 weeks (MH group: 85.3%,
NMH group 50%, P = 0.012). However, there were no sig-
nificant differences between the 2 groups with regard to
CAI (MH group: 2.8 (1–4), NMH group: 2.7 (1–4), P =
0.741), hemoglobin (MH group: 11.7 (9.6–15.6), NMH
group: 13.2 (11–15.8) g/dL, P = 0.098), albumin (MH
group: 3.8 (3–4.7), NMH group: 3.8 (2.9–4.6) g/dL, P =
0.703), CRP (MH group: 0.12 (0.04–1.15), NMH group:
0.15 (0.03–1.03) mg/dL, P = 0.665), total dose of PSL up to
remission MH group: 685 (330–1690), NMH group: 755
(335–1322) mg, P = 0.501), or use of AZA (MH group: 34/
7, NMH group: 11/3, P = 0.715) (Table 2).
Relapse rate
The relapse rate at 100 days after induction of remission
showed no significant difference between the MH and
NMH groups, being 8% in both groups. However, there
was a significant difference in the relapse rate between the
2 groups at 300 days (MH group: 17%, NMH group: 43%),
500 days (MH group: 17%, NMH group: 75%), and 1000
days (MH group: 17%, NMH group: 81%) after induction of
remission (P < 0.05) (Fig. 3, Table 3). Adverse events related
to TAC were reported as tremor, renal impairment, head-
ache, and hypomagnesemia in 7, 5, 3, and 3 patients, re-
spectively (Table 4). The prevalence of adverse events was
not different between the MH and NMH groups.




UC is a chronic inflammatory disease that repeats epi-
sodes of relapse and remission.Only 20–30% of patientsTable 2 Comparision between mucosal healing group (MH Group)
MH G
n = 4
TAC at the end of data
CAI 2.8 (1
Hb (g/dl) 11.7




Total prednisolone dose during hospitalization (mg) 685 (
Duration of TAC (days) 297.6
Combined use of AZA (yes / no) 34/7
Steroid free rate at 24 weeks
n (%)
35 (8
Data are expressed as the mean ± standard deviation or the number of patients
AZA azathioprinewith UC moderate or more relapse have difficulty in
treatment. PSL are used first in moderate or more severe
cases [2]. The patients in this study also had moderate
or worse UC. The clinical activity index (CAI) before
PSL administration was high, and the endoscopy score
(Mayo, UCEIS) was high in 42 patients who underwent
endoscopy (Table 1). Therefore, PSL was given before
TAC in all cases that were steroid-resistant or refractory.
PSL is one of the poor prognostic factors for UC. In
cases where PSL must be used, repeated relapses require
surgery [11]. Therefore, PSL use has been reported to be
one of the markers of UC severity. For intractable cases,
it is important to prevent relapse after induction and
maintain remission.
Various reports have been published on the benefits of
achieving MH and this is considered a therapeutic goal
for UC, as MH has reduced the rate of relapse [7, 12].
TAC is used to induce the remission of UC. However,
the duration of treatment with TAC is not clearly de-
fined in the ECCO Guidelines [2]. In this study, we com-
pared patients treated with TAC who achieved mucosal
healing (MH group) or did not achieve mucosal healing
(NMH group). Among the clinical characteristics that
we investigated, the age at initiation of treatment was
significantly lower in the NMH group. In this study,
TAC was started at the time of hospital admission and
was completed during outpatient follow-up, so oral ad-
ministration of TAC was managed by the patients them-
selves after discharge from the hospital. The percentage
of young people in the NMH group was high. This may
have contributed to reduced oral drug compliance.
It has been reported that compliance with internal
medicine is likely to be reduced among young people
[13]. TAC blood levels are affected by diet. Therefore,






–4) 2.7 (1–4) 0.741
(9.6–15.6) 13.2 (11–15.8) 0.098
–4.7) 3.8 (2.9–4.6) 0.703
(0.04–1.15) 0.15 (0.03–1.03) 0.665
(0–1) 2.21 (2–3) 0.001
(0–4) 4.42 (4–5) 0.001
330–1690) 755 (335–1322) 0.501
(58–922) 136.9 (70–373) 0.014
11/3 0.715
5.3%) 7 (50%) 0.012
Table 3 Relapse rate
MH Group NMH Group p-value
Relapse rate after 100 days (%) 8 8 N.S.
Relapse rate after 300 days (%) 17 43 P<0.05
Relapse rate after 500 days (%) 17 75 P<0.05
Relapse rate after 1000 days (%) 17 80 P<0.05
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oral administration becomes more complex due to other
drugs [14]. However, this study did not confirm compli-
ance with internal medicine after discharge and did not
measure frequent blood troughs.
Therefore, the decline in compliance with oral admin-
istration of young people is only speculation. Further-
more, as the clinical symptoms improve, the compliance
with oral administration tends to be further reduced
[15]. Therefore, it can be suggested that compliance of
younger patients decreases after discharge from the hos-
pital, resulting in failure to achieve MH. Other clinical
characteristics, particularly the duration of UC, CAI, and
endoscopic severity scores before initiation of TAC, were
not correlated with MH.Clinical characteristics on completion of TAC
Comparison of clinical characteristics between the MH
and NMH groups at the end of TAC revealed no signifi-
cant differences in CAI, hemoglobin, albumin, or CRP.
At the end of treatment, detailed data about clinical
characteristics and laboratory parameters were obtained
from both groups. However, there were no significant
differences in clinical or laboratory characteristics be-
tween the 2 groups, suggesting that it is difficult to pre-
dict the achievement of MH based on these factors. By
definition, there were significant differences in endo-
scopic findings between the MH and NMH groups
(Table 2, Fig. 2). Importantly, the duration of TAC was
markedly different between the MH and NMH groups,
being significantly longer in the MH group (Table 2).
There are no rules regarding the duration of TAC ad-
ministration. Therefore, the duration of TAC adminis-
tration varied from physician to attendant, resulting in a





Tremors 5 (12.1%) 2 (14.2%)
Nephropathy 4 (9.7%) 1 (7.1%)
Headache 1 (2.4%) 2 (14.2%)
hypomagnesemia 2 (4.8%) 1 (7.1%)
Data are expressed as the number of patients (percentage)This suggests the possibility that MH is more likely to
be obtained by long-term treatment with TAC. There-
fore, it may be necessary to continue TAC after clinical
remission if MH has not been achieved. There was no
significant difference in the combination of AZA be-
tween the MH group and NMH group. Therefore,
whether AZA contributed to the promotion of MH was
unclear in this study. The steroid-free rate at 24 weeks
showed a significant difference between the 2 groups.
PSL are generally the first-line treatment for moderate/
severe UC [2, 16]. If there is no response to PSL, switch-
ing therapy or the addition of other drugs is required.
When a response is noted, the PSL dosage should be ta-
pered or discontinued as soon as possible because these
drugs have no remission-maintaining effect and pro-
longed use may cause steroid dependence, leading to in-
tractability of UC [2, 16–18, 19]. In this study, TAC was
not used in the NMH group for long enough. Therefore,
MH could not be achieved in the NMH group, and
steroid-free treatment could not be achieved. TAC must
be used for a sufficient period to be steroid free.
Prolonged use of steroids may also cause a wide var-
iety of adverse events [18]. Accordingly, achievement of
a steroid-free status in UC patients is important to pre-
vent intractability of the disease and steroid-related ad-
verse events [2, 20].
Relapse rate
At 100 days after induction of remission, the relapse rate
was the same in the MH and NMH groups (MH group:
8%, NMH group: 8%), but the relapse rate showed a signifi-
cant difference between the two groups at 300 days (MH
group: 17%, NMH group: 43%), 500 days (MH group: 17%,
NMH group: 75%), and 1000 days (MH group: 17%, NMH
group: 81%) (P < 0.05) (Fig. 3, Table 3). That is the relapse
rate was lower from 300 days on in the MH group. It has
been reported that MH affects the recurrence and mainten-
ance of remission [11]. Achieving MH in infliximab studies
has been reported to contribute to the maintenance of re-
mission. Achieving MH is considered to be a target for UC
treatment. This study focused on achieving MH with TAC
[12]. Unlikely previous reports, we focused on the achieve-
ment of MH by TAC in this study.
There are few reports examining the relationship with
MH in refractory cases using TAC. Miyoshi et al. re-
ported that colonoscopy results 3 months after TAC
were associated with later relapse [21]. This study also
reports that MH was involved in maintaining remission.
However, our study differs from Miyoshi’s report in the
period of use of TAC. TAC was used until MH was
achieved to prevent relapse.
The importance of preventing relapse differs between
patients with refractory or moderate/severe UC and pa-
tients with mild UC. Refractory or relapsing moderate/
Fig. 2 Changes in the endoscopic findings of the MH group and NMH group
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mission, and intensified drug therapy, which have a det-
rimental impact on the quality of life [22, 23].
Furthermore, surgery is often required to manage pa-
tients with refractory or relapsing moderate/severe UC
[4]. Therefore, maintenance of remission is very import-
ant for refractory or relapsing moderate/severe UC.
As adverse events related to TAC therapy, tremor (7
patients), renal impairment (5 patients), headache (3 pa-
tients), and hypomagnesemia (3 patients) were observed
in the present study (Table 4). All of these events im-
proved after dosage reduction of TAC. Renal impair-
ment was improved by the addition of fluids and TAC
could be continued [24, 25].
A strength of this paper is that the total amount of








Fig. 3 Relapse rate after achieving remissionTAC trough was achieved (day), and the TAC adminis-
tration period are examined. There were several reports
on TAC and MH. However, there is no report on these
points. This suggests that this report may serve as a
standard for treatment in clinical practice.
Unfortunately, this study did not use calprotectin to
assess MH. It has been reported that calprotectin is sim-
ple and is an excellent biomarker for predicting MH and
relapse. In the future, it is necessary to consider add-
itional factors such as this [26].
The limitations of this study included its retrospect-
ive design and its collection of data from a single
center, which could have resulted in bias. To confirm
our findings, it will be necessary to perform a pro-
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TAC is effective for refractory UC, but relapse can occur
after clinical induction of remission if colonoscopy
shows that MH has not been achieved. Colonoscopy
should always be performed to evaluate the mucosal re-
sponse at completion of TAC. We suggest continuing
TAC for long-term MH.
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